Navigation Links
Development of gene therapy

Since the late 1980s, gene therapy, more than virtually any other type of therapy, has given rise not only to high expectations of treatment success but also great concerns regarding health risks. Since the Deutsche Forschungsgemeinschaft (German Research Foundation, DFG) issued its first memorandum in 1995, this field of research has developed enormously.

Wide-ranging experiments have shown the therapeutic potential as well as the risks of gene therapy. The second memorandum, which has just been presented by the DFG Senate Commission on Genetic Research, makes it clear that gene therapy already shows signs of success in certain areas, such as severe hereditary immunodeficiency diseases, while in other areas there is still considerable need for research. Moreover, the clinical application of gene therapy requires careful risk/benefit assessment, although in this respect it does not differ substantially from other therapeutic approaches.

Gene therapy is defined as the introduction of genes into tissues or cells via gene transfer, with the purpose of deriving a therapeutic or preventative benefit from the function of these genes. Gene transfer is achieved using a vector ? a kind of vehicle that carries the gene. Somatic gene transfer only targets body cells (somatic cells). Introducing genes into the germline is illegal in Germany. The first well-documented gene therapy studies were launched in the early 1990s. By 2005 it was estimated that more than 1,100 gene therapy studies had been conducted worldwide, one-third of them in Europe, and a significant number in Germany. The DFG is currently funding a Priority Programme for research groups, some of which are international leaders in their field, that examine the entry and persistence of gene therapy vectors in target cells.

In spite of continued great difficulties with technical implementation, initial successes in somatic gene therapy are on the horizon, for example in treating adenosine deam inase deficiency and chronic granulomatous disease. There are also initial indicators that point to the efficacy of gene therapy in treating chronic lymphatic leukaemia and haemophilia B. But successes in clinical testing come with their share of setbacks, such as the currently slight margin of therapeutic effectiveness over unwanted side effects. This underscores the necessity to carefully assess risks and benefits and also shows that there is still a dire need for more research on gene therapy. Basic research should be conducted in direct collaboration across disciplines, using animal models and clinical studies. An acute need for research exists, especially regarding the development of efficient and safe vectors for gene transfer.


Source:Deutsche Forschungsgemeinschaft

Related biology news :

1. Protein Packages Found To Activate Genes; May Be What Regulates Development And Disease
2. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
3. Development of portable infectious disease detector
4. Unexpressed But Indispensable -- The DNA Sequences That Control Development
5. UCSD-Salk Team Show Protein’s Gene-Silencing Role In Development of Nervous System
6. Analysis Of Human Genome To Predict The Development Of Illnesses
7. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
8. Insight into natural cholesterol control suggests novel cholesterol-lowering therapy
9. Two chemicals boost immune cells ability to fight HIV without gene therapy
10. Elevated temperature enhances success of viral cancer therapy
11. HIV mortality in India drops with introduction of generic antiretroviral therapy
Post Your Comments:

(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or "the ... results for the quarter ended September 30, 2015. ... dollars and presented under International Financial Reporting Standards ... ," said Andrew Rae , President & ... are not only value enriching for this clinical ...
(Date:11/24/2015)... 2015  Clintrax Global, Inc., a worldwide provider of clinical research ... announced that the company has set a new quarterly earnings record ... quarter growth posted for Q3 of 2014 to Q3 of 2015. ... Mexico , with the establishment of an Asia-Pacific ... United Kingdom and Mexico ...
(Date:11/24/2015)... 2015 SHPG ) announced today that ... Jaffray 27 th Annual Healthcare Conference in New ... 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
(Date:11/24/2015)... , Nov. 24, 2015  Twist Bioscience, ... that Emily Leproust, Ph.D., Twist Bioscience chief executive ... Healthcare Conference on December 1, 2015 at 3:10 ... in New York City. --> ... . Twist Bioscience is on Twitter. Sign ...
Breaking Biology Technology: